Is The Pennant Group, Inc. overvalued or undervalued?

As of 17 October 2025, The Pennant Group, Inc. has moved from an expensive to a fair valuation grade. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 35, an EV to EBITDA of 21.52, and a PEG ratio of 0.70, indicating a reasonable growth expectation relative to its price.
When compared to peers, The Pennant Group's P/E ratio of 26.98 is lower than Hims & Hers Health, Inc. at 54.76, but higher than Addus HomeCare Corp. at 22.05, suggesting a competitive positioning within its industry. Additionally, its EV to EBITDA ratio is also more favorable than Hims & Hers, which stands at 66.53. Despite recent struggles, with a YTD return of -10.86% compared to the S&P 500's 13.30%, the company's long-term performance over three years shows a strong return of 140.73%, which indicates potential for recovery and growth.